Since the partial reductions in Aβ production could mimic the putative protective effect of the Icelandic mutation (APP A673T), such studies have proposed that asymptomatic populations may benefit from the long-term administration of low-dose BACE1 inhibitors to prevent AD by ideally yielding 30% reduced Aβ production (21). The gene discussed is BACE1; the disease is Alzheimer disease.